RxDoctor Payments Data

Naresh Mody, MD

Cardiovascular Disease · Titusville, FLNPI 1669475646

Payments from drug & device makers

$9,635in general payments, 2019–2025

Across 483 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Boston Scientific$1K
  • Merck$701
  • Boehringer Ingelheim$643
  • Amgen$630
  • Novartis$552
  • plus $5K from 42 others

What the payments were for

  • Travel & lodging$3764%
  • Food & beverage$9,22096%
  • Education$390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,635 in reported general payments places this provider in the 70th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$681,727
Medicare patients
1,636
Services billed
7,563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban406$437,762
EliquisApixaban308$328,935
MounjaroTirzepatide190$209,201
EntrestoSacubitril/Valsartan139$184,409
Repatha SureclickEvolocumab119$97,057
JardianceEmpagliflozin52$67,588
BrilintaTicagrelor47$45,180
VerquvoVericiguat19$34,058
WegovySemaglutide23$29,646
VascepaIcosapent Ethyl27$25,190
OzempicSemaglutide21$18,880
Metoprolol Succinate1,108$16,892
Repatha SyringeEvolocumab20$14,675
Rosuvastatin Calcium850$13,930
ClopidogrelClopidogrel Bisulfate729$11,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$1,250$437,762406 claims
PfizerEliquis$405$328,935308 claims
Lilly USA, LLCMounjaro$44$209,201190 claims
NovartisEntresto$552$184,409139 claims
Boehringer IngelheimJardiance$643$67,58852 claims
Novo NordiskWegovy, Ozempic$130$48,52644 claims
AstraZenecaBrilinta$322$45,18047 claims
MerckVerquvo$701$34,05819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Titusville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →